




Stealth LNPs have long circulation times enabling a platform approach to target specific cell types




ctLNP stability is dependent on the sequence identity and domain orientation of antibody fragment used




Further stability improvements can be achieved through compositional changes to the base LNP




A modular bioconjugation platform transforms the stealth LNP into a cell-targeting lipid nanoparticle (ctLNP)




Stability of ctLNP can be recovered through optimization of cell targeting ligand density




Stable ctLNPs help drive high uptake and expression of reporter genes in primary human hepatocytes



Stability of ctLNPs monitored through size and encapsulation efficiency quantification



Linker chemistry impacts conjugation efficiency and stability of ctLNPs independently



Future ctLNP developments aim to reduce off-target effects while improving on-target potency

